Seracam is a game-changing molecular imaging technology aimed at improving quality of care, increasing access to care whilst reducing healthcare system costs.

Our highly experienced team have between them led the development, launch and successful commercialisation of radiopharmaceuticals, x-ray and MR contrast media as well as nuclear medicine, ultrasound, MR and CT scanners for the industry’s leading global players. We’re always ready to talk to investors who match our ambitions and can help us excel.

If you would like to learn more please contact:

Mark Rosser, CEO